Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
A vaccination strategy to prevent coxsackie virus B3–induced development of pancreatic cancer
Veethika Pandey, Heike R. Döppler, Ligia I. Bastea, Alicia K. Fleming Martinez, Barath Shreeder, Brandy H. Edenfield, Keith L. Knutson, DeLisa Fairweather, Peter Storz
Veethika Pandey, Heike R. Döppler, Ligia I. Bastea, Alicia K. Fleming Martinez, Barath Shreeder, Brandy H. Edenfield, Keith L. Knutson, DeLisa Fairweather, Peter Storz
View: Text | PDF
Research Letter Gastroenterology Immunology Inflammation

A vaccination strategy to prevent coxsackie virus B3–induced development of pancreatic cancer

  • Text
  • PDF
Abstract

Authors

Veethika Pandey, Heike R. Döppler, Ligia I. Bastea, Alicia K. Fleming Martinez, Barath Shreeder, Brandy H. Edenfield, Keith L. Knutson, DeLisa Fairweather, Peter Storz

×

Figure 1

A preclinical proof-of-principle experiment demonstrating that vaccination prevents CVB3-induced development of pancreatic cancer.

Options: View larger image (or click on image) Download as PowerPoint
A preclinical proof-of-principle experiment demonstrating that vaccinati...
(A) Timeline. (B) CVB3 capsid antibodies in blood samples at days 14 and 28 in the 4-week vaccination period via ELISA. (C) Representative pictures of IHC staining for CVB3 at endpoint. Arrows indicate CVB3+ cells. Scale bar: 100 μm. (D) H&E staining of a representative area of the pancreas. Scale bar: 1 mm. (E) Quantification of ADM, PanIN1A/B, PanIN2, and PanIN3 in CVB3 infected KC mice either vaccinated (n = 7) or vehicle treated (n = 5). P values for vehicle versus vaccinated CVB3-treated KC mice: ADM, P < 0.0001; PanIN1A/B, P < 0.0001; PanIN2, P < 0.0001. (F) Bar graph indicating the percentage of CD3+CD4+ and CD3+CD8+ T cells. (G–J) Bar graphs indicating relative change of Treg (FoxP3+ T cells), total macrophages (F4/80+ cells), Ym1+ macrophages, or SMA+ stellate cells between conditions. (K) Representative pictures of trichrome staining for n = 5 for both conditions. Scale bar: 100 μm. In B and E–J, the statistical significance between groups was determined using a 2-tailed t test. In B and F–J, data are shown as mean ± SD, and individual dots represent samples from individual mice.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts